1. Introduction {#s0005}
===============

Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by distressing and time-consuming obsessions and compulsions ([@bb0010]). Obsessions are unwanted recurrent and intrusive thoughts, images or impulses (eg. fear of contamination or harming important people) and compulsions are repetitive behaviours that aim to reduce or neutralize the distress caused by the obsessions (eg. excessive washing, checking or mental rituals). In children and adolescents, OCD is associated with functional impairments in many important areas, such as education ([@bb0170]), at home and in social relationships ([@bb0245]). Since about 70% of individuals have a symptom onset during childhood ([@bb0220]), and OCD can be chronic if left untreated ([@bb0175]), there is broad consensus in the field that early interventions should be prioritized ([@bb0055]).

There is solid evidence that cognitive behaviour therapy (CBT) is an effective psychological treatment for children and adolescents with OCD, with large effect sizes compared to both waitlist and active control conditions (*g* = 0.93--1.53; [@bb0165]). However, despite expert consensus and guidelines recommending CBT as a first-line treatment for the disorder ([@bb0060]; [@bb0160]; [@bb0225]), accessibility is low and a majority of OCD sufferers do not have access to this treatment ([@bb0095]; [@bb0155]; [@bb0190]). Possible barriers include the shortage of trained CBT therapists, high costs of treatment, and geographical factors ([@bb0125]; [@bb0205]).

In an attempt to increase access to effective treatment, several options to deliver CBT online have been developed ([@bb0040]; [@bb0250]). One of these approaches is therapist-guided Internet-delivered CBT (ICBT) which has been evaluated for adults in Australia ([@bb0255]), and Sweden ([@bb0020]; [@bb0025]). For children and adolescents with OCD, only one therapist-guided ICBT intervention has been developed and evaluated to date, called BIP OCD, which was developed in Stockholm, Sweden ([@bb0030]; [@bb0105]; [@bb0100]). BIP OCD has been evaluated in two open feasibility studies with promising results for both children (*N* = 11, within-group Cohen\'s *d* = 1.86; [@bb0030]) and adolescents (*N* = 21, within-group Cohen\'s *d* = 2.29; [@bb0100]), and showed superiority and cost-effectiveness compared to waitlist in a randomized controlled trial (RCT; *N* = 67, between-group Cohen\'s *d* = 0.69; [@bb0105]; [@bb0110]). A further RCT is currently ongoing, aiming to establish if BIP OCD in a stepped care approach is as efficacious (i.e. non-inferior) and cost-effective compared to standard face-to-face CBT for young people with OCD ([@bb0035]).

BIP OCD has so far only been evaluated in a Swedish clinical-academic setting where the intervention was developed, with the majority of participants being self-referred. There is however a need move from efficacy trials conducted in academic settings to effectiveness trials, where the treatments are evaluated in regular healthcare settings. This may be especially important in the case of ICBT as some research has suggested that the effects are smaller when delivered in routine care compared to research trials ([@bb0180]). Effectiveness studies of ICBT have been done both for adults with several mental health conditions ([@bb0015]; [@bb0230]), and for children with anxiety disorders ([@bb0085]; [@bb0090]; [@bb0145]), but comparable studies are lacking in pediatric OCD. Thus, an important next step is to investigate if the promising effects of BIP OCD are generalizable to other countries and different healthcare contexts, and more diverse patient groups. The aim of this study was therefore to evaluate the acceptability, feasibility, and preliminary effectiveness of implementing BIP OCD in three different clinics in Sweden, United Kingdom and Australia, where the intervention had not been tested before, and where patients were mainly clinician-referred. Specifically, we report on treatment adherence, outcome data, and therapists\' views on the advantages and disadvantages of this treatment modality.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

BIP OCD was evaluated at three different sites using an open trial design (repeated measurements). As per the original BIP OCD trials, the duration of the treatment was 12 weeks. The sites were located in Gothenburg (specialized Child and Adolescent Psychiatry unit for OCD at Sahlgrenska University Hospital, Sweden), London (National Specialist Clinic for Young People with OCD, BDD and related disorders at South London and Maudsley NHS Foundation Trust, United Kingdom), and Brisbane (the School of Psychology at University of Queensland, Australia). The clinic in Gothenburg is a specialized unit that receives both self-referrals and clinician-referrals from Child and Adolescent Mental Health Services within the region, but also accepts referrals from other parts of Sweden. The London clinic is a national service clinic that receives referrals from all parts of United Kingdom, and tend to see severe or complex cases where a majority of the patients have had previous treatment for OCD. The Brisbane site is a University clinic, that tends to attract patients who live out of regional cities where there is limited access to healthcare services, and receives mainly self-referrals from parents who feel that their children would be unwilling to go to a clinic and instead engage better with an online intervention. Each site received local ethical approval (Gothenburg ID 2016/2161-32; London ID 16/WA/0064; Brisbane ID UQ_IHREA_2015000406).

2.2. Participants {#s0020}
-----------------

Inclusion and exclusion criteria were similar across sites, with small differences, described here. Inclusion criteria were a primary diagnosis of OCD as defined by DSM-5 (Gothenburg and Brisbane; [@bb0010]) or ICD-10 (London; [@bb0260]), and a total score of ≥16 on the Children\'s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; [@bb0185]). The age criteria were between 7 and 17 years (Gothenburg) or 12 and 18 years (London and Brisbane). Additional criteria were ability to read and write Swedish (Gothenburg) or English (London and Brisbane), daily access to the Internet, a parent or caregiver that could participate in the treatment, a requirement to live in the country where the trial was conducted, and for participants on psychotropic medication, a stable dose for the last six weeks prior to baseline assessment.

Exclusion criteria were a comorbid diagnosis of global learning disabilities, autism spectrum disorder, psychosis or bipolar disorder, anorexia nervosa, or a severe neurological condition; active suicidal ideation; ongoing substance dependence (London and Brisbane); not being able to read or understand the basics of the ICBT material; received CBT for OCD within the last year (Gothenburg); presenting with very severe OCD symptoms (a total score of \>35 on the CY-BOCS, Brisbane); and ongoing psychological treatment for OCD or an anxiety disorder. All participants gave written informed consent to participate prior to inclusion.

2.3. Measures {#s0025}
-------------

### 2.3.1. Diagnostic measures {#s0030}

The diagnostic interview was done using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID; [@bb0210]) in Gothenburg and Brisbane, and the Anxiety Disorders Interview Schedule for the DSM-IV (ADIS; [@bb0005]) in London.

### 2.3.2. Treatment adherence and therapist support time {#s0035}

The number of completed modules and the number of individuals classed as treatment completers were used as measures of treatment adherence. Treatment completers were defined as individuals completing the first active treatment module, containing exposure with response prevention (ERP).

The amount of therapist time supporting each family was recorded. It includes time spent on correspondence with both child and the parents as well as additional phone calls if required. Both the average therapist time per family for the whole treatment and the average therapist time per week in treatment (therapist time divided by number of modules completed) were calculated.

### 2.3.3. Primary outcome measure {#s0040}

The primary outcome measure was the CY-BOCS ([@bb0185]), which is a semi-structured, clinician-rated interview to determine the severity of OCD symptoms in children and adolescents. It consists of a symptom checklist and a 10-item severity scale. Each item is rated on a 5-point scale, which yields a total severity score ranging from 0 to 40, with higher scores indicating more severe symptoms. It has good to excellent interrater reliability, high internal consistency and good short-term test-retest reliability ([@bb0045]; [@bb0185]; [@bb0215]).

### 2.3.4. Secondary outcome measures {#s0045}

The clinician-rated CGAS ([@bb0195]) is a clinician-rated global measure of functional impairment. It is scored from 0 to 100, with higher scores indicating better functioning. CGAS is reliable between raters and across time, and has demonstrated both discriminant and concurrent validity ([@bb0195]).

The Children\'s Obsessional Compulsive Inventory Revised -- Parent (ChOCI-R-P; [@bb0240]), the revised version of the ChOCI ([@bb0200]), is a 32-item parent-rated measure of OCD symptom severity that includes both symptoms and severity items. The total impairment score is based on the 12 severity items and range from 0 to 48, with higher scores indicating more OCD symptoms. ChOCI-R-P has demonstrated good internal consistency and criterion validity ([@bb0240]).

The Work and Social Adjustment Scale -- Youth and Parent versions (WSAS-Y/P; [@bb0080]) is a 5-item measure of general functional impairment related to psychopathology. The WAS-Y/P is a child and parent adaptation of the adult WSAS measure (David [@bb0135]; [@bb0150]). The total score ranges from 0 to 40. Both the child and parent versions possess good internal consistency, test-retest reliability, convergent validity, and sensitivity to change ([@bb0080]).

### 2.3.5. Feedback from therapists {#s0050}

The therapists provided feedback about the feasibility and acceptability of delivering BIP OCD within their services by answering open questions about advantages and/or concerns they had with the treatment and what they considered important in implementing the treatment (see supplement S3). The feedback from therapists was summarized and grouped into specific themes.

2.4. Procedures {#s0055}
---------------

Participants were consecutively recruited from routine clinical referrals to the Gothenburg and London clinics. In Brisbane, participants could either be referred by a clinician or be self-referred, and the trial was advertised both online, in media, and via flyers in offices of general practitioners. Eligible participants were assessed by a clinician either at a face-to-face appointment (Gothenburg and London) or via the phone (Brisbane). The assessment included a diagnostic interview using the MINI-KID ([@bb0210]) or the ADIS ([@bb0005]), the clinician-rated measures CY-BOCS for baseline OCD symptom severity and CGAS ([@bb0195]) for global functioning, and all self- and parent-rated measures. All participants and parents/caregivers provided written informed consent to participate prior to inclusion during this visit.

After 12 weeks of treatment, a post-treatment assessment was conducted including all clinician-, self- and parent-rated measures. The same procedure was repeated 12 weeks later (3-month follow-up). The assessments at post-treatment and 3-month follow-up were conducted by a different clinician than the treating therapist. [Fig. 1](#f0005){ref-type="fig"} shows the study flow with an overview of the inclusion and assessment points, by study site.Fig. 1Study flow chart.Fig. 1

2.5. Intervention {#s0060}
-----------------

Two different language versions of BIP OCD exist. The London and Brisbane sites employed the English version of BIP OCD, which is a translation of the original BIP OCD intervention directed to adolescents by [@bb0105]. This version of BIP OCD consisted of 12 modules for the adolescent and five parallel modules for parents. The Gothenburg site employed an updated version of BIP OCD, which was expanded to suit both children and adolescents with OCD, based on pilot work by [@bb0030]. The updated BIP OCD version, only available in Swedish, included more parent modules (12 modules) and introduces the core treatment ingredient ERP earlier. See [Table 1](#t0005){ref-type="table"} for an overview of the treatment content.Table 1Treatment overview.Table 1ChapterSwedish BIP OCDEnglish BIP OCDChild/AdolescentParentAdolescentParentEducation1What is OCD?Education about OCD and the OCD circleIntroduction to ICBTIntroduction to ICBT2How to get rid of OCD?About CBT and treatment goalsEducation about OCDEducation about OCD3What is exposure?About exposure and response preventionThe OCD circle  Exposure with response prevention4Testing exposureParent strategies during exposureBuilding an exposure hierarchy5Continue with exposureMore about exposureAbout exposure and response preventionAbout exposure and response prevention6When OCD affects the familyAbout family accommodationTesting exposureParental strategies during exposure7More exposureMotivation and parent strategiesMore exposure8Coping with obsessionsCoping with obsessionsExposure, frequent problems and solutionsAbout family accommodation9New steps with exposureEvaluate the treatmentNew steps with exposure10Using re-exposure techniquesUsing re-exposure techniquesCoping with obsessions11Perform a more difficult exposurePerform a more difficult exposureFinal exposure exercises  Relapse prevention12Plan for the futurePlan for the futureRelapse prevention and lessons learned[^1]

To enable access to BIP OCD, all participants and parents/legal guardians were given separate logins to a secure webpage through which the treatment was delivered. The intervention followed recommendations from established guidelines ([@bb0060]; [@bb0160]; [@bb0225]), and included psychoeducation, ERP, and relapse prevention. Each module consists of text, brief video clips, animations, examples, and exercises that helped the participant and parents to learn about OCD, create an ERP hierarchy and how to implement and practice ERP tasks in everyday situations. Throughout the treatment, each family had contact with a designated therapist who provided asynchronous, predominantly written, support with occasional telephone calls if needed. Therapists assisted with planning, problem-solving and encouraged compliance with ERP and homework tasks. The following video illustrates the main features of BIP OCD: <https://vimeo.com/355965105/b3d5d1c439>.

All therapists (three in Gothenburg, two in London and one in Brisbane) were highly experienced in the delivery of face-to-face CBT for young people with OCD within specialized care. The Gothenburg team had a two-day workshop prior to starting ICBT as well as weekly supervision during the trial from two of the authors (KA and FL), while the London and Brisbane teams received training videos about BIP OCD and videoconference supervision on demand.

2.6. Data analysis {#s0065}
------------------

A series of mixed-effect regression analyses with maximum likelihood estimation were conducted on the outcome measures to detect statistical change between the assessment points ([@bb0065]; [@bb0070]). Adding site, number of completed chapters or therapist time as a covariate did not improve the model fit, and were not included in the final model. Effect sizes (Cohen\'s *d*) was estimated with the m_effectsize command in STATA developed by Karolinska Institutet Biostatistics Core Facility and available at [www.imm.ki.se/biostatistics/stata](http://www.imm.ki.se/biostatistics/stata){#ir0010}. The α value (2-tailed) was set at *p* \< .05 for all analyses. A sensitivity analysis was made as recommended when the missing data is above 5% ([@bb0075]). This was done using multiple imputation by chained equations with predictive mean matching on 20 imputed datasets, to check if the raw versus imputed datasets yielded similar results. Statistical analyses were conducted using STATA version 14.2 (StataCorp LLC).

3. Results {#s0070}
==========

3.1. Sample characteristics and study flow {#s0075}
------------------------------------------

Thirty-one patients participated in the current study (Gothenburg: *n* = 13; London: *n* = 9; Brisbane: *n* = 9). Demographic and clinical characteristics of the patients are presented both for the total group and by study site in [Table 2](#t0010){ref-type="table"}. The average age was 14.0 years (SD = 2.3), 41.9% (*n* = 10) had received previous CBT for OCD, and more than half (54.8%; *n* = 17) had at least one comorbid disorder, out of which specific phobia was the most prevalent. All patients in Gothenburg and London, and 33.3% (*n* = 3) in Brisbane were clinician-referred. The other Brisbane participants were self-referred following advertising of the study. As shown in [Fig. 1](#f0005){ref-type="fig"}, Gothenburg had complete primary outcome data on the clinician-rated measures on all assessment points, London had 66.7% complete data (*n* = 6/9) on both post-treatment and 3-month follow-up assessments, and Brisbane had 44.4% complete data (*n* = 4/9) at post-treatment and 22.2% (*n* = 2/9) at the 3-month follow-up assessment.Table 2Baseline demographic and clinical characteristics of the sample (*N* = 31).Table 2Total sampleGothenburg (*n* = 13)London (*n* = 9)Brisbane (*n* = 9)Gender, *N* (%) Girls21 (67.7)7 (53.9)6 (66.7)8 (88.9)Age (years) Mean (SD), range14.0 (2.3), 8--1813.2 (2.6), 8--1715.6 (2.0), 13--1813.6 (1.2), 12--16Distance to clinic (km) Median, range16, 2--243514, 2--4113, 2--4381443, 9-2435^a^Main contact person, *N* (%) Mother25 (80.7)8 (61.6)8 (88.9)10 (100)Psychotropic medication for OCD, *N* (%) Previous3 (9.7)0 (0)1 (11.1)2 (22.2) Current7 (22.6)2 (15.4)5 (55.6)0 (0)Previous psychological treatment, *N* (%) CBT for OCD10 (41.9)3 (23.1)4 (44.4)3 (33.3) CBT for other4 (12.9)0 (0)1 (11.1)3 (33.3) Other4 (12.9)1 (7.7)1 (11.1)2 (22.2)Presence of comorbid diagnosis, *N* (%) Yes17 (54.8)5 (38.5)5 (55.6)7 (77.8)Frequency of comorbid diagnosis, N (%) BDD1 (3.2)0 (0)1 (11.1)0 (0) Skin-picking disorder1 (3.2)1 (7.7)0 (0)0 (0) Specific phobia8 (25.8)2 (15.4)0 (0)6 (66.7) Social anxiety disorder5 (16.1)1 (7.7)0 (0)4 (44.4) Separation anxiety1 (3.2)0 (0)1 (11.1)0 (0) GAD3 (9.7)1 (7.7)1 (11.1)1 (11.1) Agoraphobia1 (3.2)1 (7.7)0 (0)0 (0) Depressive disorder3 (9.7)1 (7.7)2 (22.2)0 (0) Tic disorder2 (6.5)0 (0)0 (0)2 (22.2) ADHD2 (6.5)1 (7.7)0 (0)1 (11.1)CY-BOCS total score Mean (SD), range24.6 (3.5), 17--3124.1 (3.2), 17--2924.9 (4.7), 18--3025.0 (2.9), 21--31Referral source Clinician-referred25 (80.1)13 (100)9 (100)3 (33.3)^a^[^2][^3]

3.2. Treatment adherence and therapist support time {#s0080}
---------------------------------------------------

The average module completion was 8.1/12 (SD = 3.2). There was no significant effect of site on module completion (F(2) = 1.22, *p* = .31). Patients completed on average 76% (M = 9.1/12, SD = 2.3) of the modules in Gothenburg, 65% (M = 7.8/1, SD = 3.0) in London, and 58% (M = 7/12, SD = 4.2) in Brisbane. The parents completed an average of 77% (M = 9.2/12, SD 2.5) of the modules in Gothenburg, 62% (M = 3.1/5, SD = 2.1) in London, and 78% (M = 3.9/5, SD 1.3) in Brisbane.

The number of treatment completers differed by site (χ2 (2, *N* = 31) = 8.79, *p* = .02). Gothenburg had a higher degree of treatment completers (100%; *n* = 13) compared with London (55.6%; *n* = 5; *p* \< .01) and Brisbane (55.6%; n = 5, *p* = .01). The average therapist support time for the whole treatment were 411.8 min (SD = 178.8, median = 360) in Gothenburg, 159.6 min (SD = 107.2, median = 98.0) in London, and 153.3 min (SD = 117.0, median = 146.0) in Brisbane. This corresponds to an average therapist time per week in treatment of 44.6 min (SD = 11.7, median = 41.5) in Gothenburg, 19.1 min (SD = 7.0, median = 20.3) in London, and 19.3 min (SD = 8.6, median = 19.7) in Brisbane, which is a significant effect of site on total therapist time (F(2) = 25.64, *p* \< .000) with Gothenburg spending more time per patient than in London (*p* \< .001) and Brisbane (*p* \< .001).

3.3. Clinical outcome measures {#s0085}
------------------------------

[Table 3](#t0015){ref-type="table"} shows the observed means and standard deviations on all measures by assessment point, and the estimated mean values and effect sizes between baseline to post-treatment and post-treatment to the 3-month follow-up. For descriptive purposes, the observed values by site are reported in the supplement (S1).Table 3Observed means and standard deviations, estimated means and effect sizes (bootstrapped Cohen\'s *d*).Table 3MeasureObserved valuesEstimated valuesEffect sizesBaselinePost-treatment3-month follow-upPost-treatment3-month follow-upBaseline -\
Post-treatmentPost-treatment -\
3-month follow-upMean (SD)Mean (SD)Mean (SD)MeanMeanCohen\'s *d* (95% CI)Cohen\'s *d* (95% CI)CY-BOCS24.58(3.54)15.61(6.81)12.95(8.75)15.80[⁎⁎](#tf0010){ref-type="table-fn"}15.61[⁎](#tf0005){ref-type="table-fn"}1.78(1.18, 2.39)0.27(0.02, 0.51)CGAS52.35(7.41)61.14(10.03)64.86(13.97)61.89[⁎⁎](#tf0010){ref-type="table-fn"}61.291.15(0.76, 1.54)0.29(−0.08, 0.65)ChOCI-R-P25.72(8.48)18.68(9.08)15.67(9.97)18.14[⁎⁎](#tf0010){ref-type="table-fn"}18.680.92(0.42, 1.43)0.23(−0.05, 0.50)WSAS-Y13.37(6.49)9.05(5.70)7.70(5.90)8.61[⁎⁎](#tf0010){ref-type="table-fn"}9.110.77(0.27, 1.27)0.30(−0.18, 0.77)WSAS-P12.55(8.94)9.10(8.00)8.44(7.54)7.86[⁎⁎](#tf0010){ref-type="table-fn"}8.990.56(0.27, 0.84)0.08(−0.29, 0.45)[^4][^5][^6]

The analyses showed significant improvements on all the outcome measures between baseline and post-treatment, with a large within-group effect size on the CY-BOCS (bootstrapped Cohen\'s *d* = 1.78; 95% CI 1.18--2.39) and the secondary outcome measures, except on WSAS-P, which showed a moderate effect size. All results were sustained at the 3-month follow-up, and an additional reduction from post-treatment to the 3-month follow-up on the CY-BOCS (bootstrapped Cohen\'s *d* = 0.27; 95% CI 0.02--0.51). The results from the sensitivity analysis based on the multiple imputed datasets yielded similar results, except for on WSAS-P which was not significant from baseline to post-treatment. Details from the sensitivity analysis are presented in the supplement (S2).

3.4. Feedback from the therapists {#s0090}
---------------------------------

Among the advantages reported by the therapists were the efficient use of therapist time, convenience and availability for families, and that the parents are included as co-therapists. Reported difficulties were to get a detailed assessment of how much some patients adhered to the ERP exercises, and to sufficiently engage and influence the patients through the written online format compared with the traditional face-to-face format. Therapists perceived that the treatment was less suitable for patients with more complex symptoms, such as mental compulsions, rigid rules, and reading/writing compulsions, as well as for those who have not responded sufficiently to previous treatment or were ambivalent to CBT. Important aspects that were identified for successful implementation of BIP OCD in routine healthcare were to develop guidelines regarding which patients may be best suited to ICBT in terms of patient motivation prior to initiating ICBT, have routines for risk monitoring, and the importance of therapist training on how to deliver ICBT (e.g. how to give optimal support online and cope with inactive participants). Detailed therapist feedback by study site is presented in the supplement (S3).

4. Discussion {#s0095}
=============

The aim of this study was to extend findings from the previously conducted BIP OCD trials to other countries and clinics within different healthcare contexts. Prior to this study, BIP OCD had only been evaluated in a clinical-academic setting in Stockholm, where it was originally developed. In contrast to previous BIP OCD trials, which mainly recruited self-referred participants, a defining feature of the study was the enrolment of primarily clinician-referred patients. The current study therefore fills an important clinical research gap by moving beyond efficacy trials and beginning to investigate effectiveness of the intervention in regular healthcare contexts.

Overall, we observed a high degree of adherence to the BIP OCD intervention with at least 62--78% of treatment modules completed, and a majority of patients being classified as completers (56--100%). The Gothenburg site had higher degree of treatment completers than London and Brisbane. This was partly expected as the updated version of BIP OCD used in Gothenburg introduces the active treatment component ERP earlier within the intervention (in module 4 versus module 6), which may have contributed to greater treatment adherence in this site. The higher level of parental involvement (12 versus 5 modules) could also be an important aspect, but the importance of parental involvement in ICBT for pediatric OCD is still an empirical question. The differences in versions of BIP OCD and adherence between the sites are limitations of the study. Another significant difference was that the therapists in Gothenburg spent substantially more time on each family (45 versus 19 min per patient per week). This may reflect the greater number of parental modules in the updated version of BIP OCD. An additional difference was that the clinicians in the Gothenburg site received an initial two-day workshop on how to deliver BIP OCD as well as weekly supervision during the trial, which was more systematic and frequent than in the other two sites. Altogether, this may have contributed to the higher degree of treatment completers and lack of data loss at this particular site. We recommend that future studies use the most recent version of BIP OCD, that clinicians supporting the families receive specific training before starting treatment, and that they have several patients to be efficient in the online delivery. Furthermore, regular supervision of clinicians is recommended, just as in regular clinic-based CBT.

Some of the observed site differences in treatment completers and data loss might be attributable, at least in part, to the different healthcare systems. Although Sweden, the United Kingdom, and Australia all have tax-funded universal healthcare systems, each have a different financial model. The healthcare in Sweden is mostly provided by the tax-funded county councils. The specialist OCD clinic in Gothenburg receives referrals from primary care and from local child and adolescent mental health units ([@bb0140]), and typically sees both treatment naïve and treatment resistant patients mainly from the large urban areas. The London clinic is a national specialist service, and mostly sees cases of young people who have been through their local services, considered to be more severe and treatment-resistant, and who had waited many years for specialist treatment ([@bb0095]). Australia utilizes both insurance-based and user-pays systems, as tax-funded healthcare is limited in accessibility due to strict entry criteria for mental health services and where tax-funded services are more often available in urban cities and centers, with limited or no service available in rural and regional areas. A large proportion of the families who seek treatment through the University clinic in Brisbane are families who "fall through the gap" if they fail to meet entry criteria for tax-funded services, do not live geographically close to services, or do not have the financial means to access insurance-based or user-pays systems. Altogether, these financial and organizational differences may well have affected participant retention. Overall, it is clear that the implementation of e-health solutions, such as BIP OCD, should be done with full consideration of the local healthcare idiosyncrasies.

The 3-month outcomes on both primary and secondary outcome measures were largely comparable to those of the previous BIP OCD trials, with similar within-group effect sizes and an observed additional improvement between post-treatment and the 3-month follow-up ([@bb0030]; [@bb0105]; [@bb0100]). Although the validity of the results might have been affected by the number of participants attending the follow-up appointments or potential site differences, the estimated values are somewhat higher than the observed values and provide a more realistic estimate of the treatment effect. Further, the study was not conceived, or had statistical power, to examine site differences in treatment outcome, but visual inspection of the data indicated some potential site differences, as presented in the supplement. While this is an uncontrolled study, the results were encouraging and suggest that it may be possible to implement this treatment modality in regular healthcare settings with regular clinician-referred patients, even though further research is needed to establish the effectiveness of the treatment in these contexts. The optimal model for implementation of therapist-guided internet-based interventions is currently unclear and a matter of utmost importance, because it is unlikely that BIP OCD is suitable for all patients ([@bb0115]). One attractive model of healthcare delivery may be a stepped-care approach whereby patients with mild to moderate symptom severity who are willing to try this treatment format may be offered it in the first instance. In case of insufficient response, these patients could then be offered regular face-to-face CBT with a clinician, or more complex interventions in the context of a multidisciplinary team that can also offer additional treatment strategies, such as pharmacotherapy ([@bb0130]). A stepped-care approach where counseling with bibliotherapy as the first treatment step was evaluated in a small trial of adults with OCD ([@bb0235]), and our ongoing non-inferiority trial ([@bb0035]) is designed to directly address these important questions regarding ICBT for pediatric OCD.

The therapists were generally satisfied with the digital format of the treatment delivery and perceived to be a convenient way of receiving treatment for the families, with reduced travel distances, flexibility to work with the treatment when suitable, access treatment information on multiple occasions, and possibility to have a daily contact with the therapist. The BIP OCD treatment is also time efficient for the therapists with reduced therapist time and no late cancelations or missed appointments. Some therapists in this study experienced some difficulty in gauging exactly how much ERP the participants were actually completing. They also found it somewhat difficult to support participants using written text, as compared to traditional face-to-face format, as many young people did not write a lot of text. This is not so surprising as participants in ICBT tend to work more autonomously and written responses are sometimes limited in self-help treatments. Furthermore, many therapists thought that the BIP OCD treatment was harder to deliver to patients with more complex clinical symptoms such as mental compulsions, rigid rules, and reading/writing compulsions. Future development of BIP OCD may require attention to less common symptom presentations, which may be insufficiently covered in the current iteration of the intervention.

There were several limitations in this study that need to be acknowledged. First, this was an open study and it did not have a control group condition. Thus, some of the observed changes may not be entirely attributable to the intervention. Second, this study piloted the implementation of BIP OCD in three highly industrialized and wealthy cities; it cannot be automatically assumed that the results would be similar in other parts of the world, such as low or medium income countries ([@bb0050]), or countries with different healthcare systems (e.g. insurance based systems). Another limitation of this study was that slightly different inclusion- and exclusion criteria were used between the different sites, mainly due to practical reasons. This may have introduced some unwanted variability in the data. Further, the qualitative feedback was not formally analysed, since the information was not gathered in a structured way, and all therapists are co-authors of the study. Finally, there were no evaluation of clinician adherence in the current study, and patient adherence was pragmatically conceptualized as number of completed chapters and number of individuals classed as treatment completers. However, measuring adherence to e-health interventions may be more complex ([@bb0120]).

To conclude, the results in this study indicate that BIP OCD is a promising and potentially effective treatment for children and adolescents with OCD in a range of different healthcare settings in three different developed countries. This suggests that ICBT for pediatric OCD may be transferrable to outpatient clinics, though further evaluations are needed. Lessons learned are the need for continuous revision of the intervention, and the importance for future evaluations to gather data also for the non-completers. Additional improvements can be expected in BIP OCD from post-treatment to the 3-month follow-up and one opportunity for future trials is to test the treatment within a stepped care model. Implementation success is likely to be highly dependent on the specific healthcare context and on the adequate training of personnel delivering the treatment.

Declaration of competing interest
=================================

Dr. Andersson reports receiving book royalties outside the submitted work. Dr. Turner reports receiving personal fees for editorial work from British Journal of Clinical Pharmacology and book royalties outside the submitted work. Prof Mataix-Cols reports receiving personal fees for editorial work from Elsevier and royalties for contributing articles to UpToDate, Inc., all outside the submitted work. The remaining authors report no conflicts of interest.

Appendix A. Supplementary data {#s0110}
==============================

S1. Observed mean and standard deviations by study siteS2. Estimated baseline mean and change using multiple imputation by chained equationsS3. Detailed feedback from the therapists, by study site.Image 1

Acknowledgements {#s0100}
================

We thank all the participants and parents who participated in the trials. We also thank the management teams at the three clinics for support.

Funding {#s0105}
=======

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Georgina Krebs is funded by an MRC Clinical Research Training Fellowship (MR/N001400/1).

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.invent.2020.100308>.

[^1]: Abbreviations: OCD, obsessive-compulsive disorder; CBT, cognitive behaviour therapy; ICBT, internet-delivered cognitive behaviour therapy.

[^2]: Note: Site differences were calculated with a Bonferroni-corrected analysis. Subscripts (^a^) indicates a significant difference from the other sites.

[^3]: Abbreviations: ADHD, Attention Deficit/Hyperactivity Disorder; CY-BOCS, Children\'s Yale-Brown Obsessive-Compulsive Scale.

[^4]: Abbreviations: CY-BOCS, Children Yale-Brown Obsessive-Compulsive Scale; CGAS, Children\'s Global Assessment Scale; ChOCI-R-P, Children\'s Obsessional Compulsive Inventory -- Revised -- Parent version; WSAS-Y, Work, and Social Adjustment Scale -- Youth version, WSAS-P, Work, and Social Adjustment Scale -- Parent version.

[^5]: *p* \< .01.

[^6]: *p* \< .001.
